A new SARS-CoV-2 IgG test from Randox Laboratories, Crumlin, UK, utilizes patented Randox biochip technology to simultaneously detect IgG antibodies that are reactive to both of the leading covid-19 diagnostic antigens—spike receptor binding domain (RBD) and nucleocapsid protein (NP).
Simultaneously detecting both RBD-only and NP-only responders maximizes test sensitivity, making it superior to covid-19 IgG tests that are based on either RBD or NP alone, which can produce false negative results.
The Randox SARS-CoV-2 IgG (RBD & NP) Array offers clinicians an opportunity to discriminate vaccinated individuals from those naturally infected by covid-19.
“When there is little or no access to molecular testing, serology tests provide a means to quickly triage suspected cases of covid-19, enabling appropriate case management and guiding public health measures, such as quarantine or self-isolation,” says Lynsey Adams, clinical marketing manager for Randox. “The new Randox SARS-CoV-2 IgG (RBD & NP) Array provides a unique insight into disease severity, is an established method of indirect disease diagnosis, and facilitates epidemiological surveillance as the COVID-19 pandemic progresses.”
The Randox SARS-CoV-2 IgG (RBD & NP) Array has been developed for the Evidence Investigator, a semi-automated benchtop immunoassay analyzer delivering accurate results in just 1.5 hours.
Features of the new Randox SARS-CoV-2 IgG (RBD & NP) Array:
- Utilizes established diagnostic antigen candidates – RBD and NP
- IgG measurement confirms adaptive immune response to SARS-CoV-2
- Clinical specificity of 99.5%
- Clinical sensitivity of 100% ≥ 14 days post SARS-CoV-2 PCR confirmation
- Dual sample matrix: human serum/plasma.
For more information, visit Randox Laboratories.
Featured image: The Evidence Investigator by Randox Laboratories consolidates immunoassay, molecular protein, and DNA-based biochips.